With Clue and Lovehoney as partners, Evaro secures €21 million to expand NHS-licensed embedded health services

Evaro, a UK-based digital healthcare platform, has secured €21 million in Series A funding, signaling a significant expansion in its mission to integrate licensed health services directly into consumer brands. This capital injection will fuel Evaro's growth into new treatment areas like women's health, men's health, and longevity medicine, alongside enhancing clinical capabilities and platform development with a focus on API-first infrastructure for seamless brand integration. The company already boasts partnerships with prominent entities such as period-tracking app Clue and sexual wellness retailer Lovehoney, demonstrating its successful model of embedding prescription services into existing user experiences. This funding round underscores a broader trend within the European HealthTech sector, characterized by a surge in investment towards regulated, platform-driven, and clinically focused digital healthcare solutions. Similar to Evaro's trajectory, Spain's Tucuvi recently raised €17 million for its voice-AI platform, while the UK's GlycanAge received €7.4 million for its glycan-based diagnostics. These investments collectively highlight a growing European commitment to developing scalable healthcare infrastructure and digital platforms designed to alleviate strain on public health systems through technology-enabled care. The strategic implications of Evaro's expansion are far-reaching, particularly concerning the accessibility and efficiency of healthcare delivery within the European Union. By leveraging existing trusted consumer brands, Evaro is making regulated healthcare services as accessible as online banking, addressing critical issues like GP waiting times and enhancing overall patient care. This approach not only unlocks significant latent demand but also supports national health services by providing alternative, technology-driven solutions for common health conditions.